This article was originally published in The Gray Sheet
Executive SummaryFirm agrees to buy a majority interest in OST Developpement SA from parent Transphyto SA in a two-step transaction valued at $1.5 mil. The deal entails the June 25 purchase of 5% interest in the company; an additional 85% stake will be acquired no later than March 1999, provided OST achieves certain milestones, Osteotech says. The agreement allows for the purchase of the remaining 10% of OST at an undetermined price. Purchase of the French bovine bone graft manufacturer is expected to add $4 mil. to Osteotech's top-line and be accretive to earnings in 1999
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.